DE102010014290A1 - Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen - Google Patents

Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen Download PDF

Info

Publication number
DE102010014290A1
DE102010014290A1 DE102010014290A DE102010014290A DE102010014290A1 DE 102010014290 A1 DE102010014290 A1 DE 102010014290A1 DE 102010014290 A DE102010014290 A DE 102010014290A DE 102010014290 A DE102010014290 A DE 102010014290A DE 102010014290 A1 DE102010014290 A1 DE 102010014290A1
Authority
DE
Germany
Prior art keywords
agent
herpes
prophylactic
infections
therapeutic treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE102010014290A
Other languages
German (de)
English (en)
Inventor
wird später genannt werden Erfinder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hov De GmbH
Slomianny Jan De
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE102010014290A priority Critical patent/DE102010014290A1/de
Priority to DK11001816.5T priority patent/DK2374461T3/en
Priority to PL11001816T priority patent/PL2374461T3/pl
Priority to ES11001816.5T priority patent/ES2612584T3/es
Priority to EP11001816.5A priority patent/EP2374461B1/de
Priority to PCT/EP2011/001704 priority patent/WO2011124366A1/de
Priority to JP2013503032A priority patent/JP6158077B6/ja
Priority to CA2795334A priority patent/CA2795334C/en
Priority to CN201180021384.XA priority patent/CN103153312B/zh
Priority to RU2012147474/15A priority patent/RU2555765C2/ru
Priority to US13/639,357 priority patent/US20130190301A1/en
Publication of DE102010014290A1 publication Critical patent/DE102010014290A1/de
Priority to US14/167,676 priority patent/US20140148447A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE102010014290A 2010-04-08 2010-04-08 Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen Ceased DE102010014290A1 (de)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DE102010014290A DE102010014290A1 (de) 2010-04-08 2010-04-08 Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen
DK11001816.5T DK2374461T3 (en) 2010-04-08 2011-03-04 Piroxicam for the prophylactic and therapeutic treatment of herpes infections
PL11001816T PL2374461T3 (pl) 2010-04-08 2011-03-04 Piroksykam do profilaktycznego i terapeutycznego leczenia zakażeń opryszczką
ES11001816.5T ES2612584T3 (es) 2010-04-08 2011-03-04 Piroxicam para el tratamiento profiláctico y terapéutico de infecciones por herpes
EP11001816.5A EP2374461B1 (de) 2010-04-08 2011-03-04 Piroxicam zur prohylaktischen und therapeutischen Behandlung von Herpes-Infektionen
PCT/EP2011/001704 WO2011124366A1 (de) 2010-04-08 2011-04-06 Piroxicam zur prophylaktischen und therapeutischen behandlung von herpes - infektionen
JP2013503032A JP6158077B6 (ja) 2010-04-08 2011-04-06 ヘルペス感染症の予防措置及び治療措置のためのピロキシカム
CA2795334A CA2795334C (en) 2010-04-08 2011-04-06 Agent for prophylactic and therapeutic treatment of herpes infections
CN201180021384.XA CN103153312B (zh) 2010-04-08 2011-04-06 用于预防性治疗和治疗性治疗疱疹感染的吡罗昔康
RU2012147474/15A RU2555765C2 (ru) 2010-04-08 2011-04-06 Пироксикам для профилактического и терапевтического лечения герпетических инфекций
US13/639,357 US20130190301A1 (en) 2010-04-08 2011-04-06 Piroxicam for prophylactically and therapeutically treating herpes infections
US14/167,676 US20140148447A1 (en) 2010-04-08 2014-01-29 Agent for prophylactic and therapeutic treatment of herpes infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010014290A DE102010014290A1 (de) 2010-04-08 2010-04-08 Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen

Publications (1)

Publication Number Publication Date
DE102010014290A1 true DE102010014290A1 (de) 2011-10-13

Family

ID=43970974

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102010014290A Ceased DE102010014290A1 (de) 2010-04-08 2010-04-08 Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen

Country Status (11)

Country Link
US (2) US20130190301A1 (cg-RX-API-DMAC7.html)
EP (1) EP2374461B1 (cg-RX-API-DMAC7.html)
JP (1) JP6158077B6 (cg-RX-API-DMAC7.html)
CN (1) CN103153312B (cg-RX-API-DMAC7.html)
CA (1) CA2795334C (cg-RX-API-DMAC7.html)
DE (1) DE102010014290A1 (cg-RX-API-DMAC7.html)
DK (1) DK2374461T3 (cg-RX-API-DMAC7.html)
ES (1) ES2612584T3 (cg-RX-API-DMAC7.html)
PL (1) PL2374461T3 (cg-RX-API-DMAC7.html)
RU (1) RU2555765C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011124366A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010014290A1 (de) * 2010-04-08 2011-10-13 Hans Otto Meyer zu Spelbrink Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen
DE102013003756A1 (de) 2013-03-06 2014-09-11 DeaValorum UG (haftungsbeschränkt) Piroxicam zur prophylaktischen und therapeutischen Behandlung von CMV-Infektionen
DE102013014787A1 (de) 2013-09-09 2015-03-12 Dauphine UG (haftungsbeschränkt) Mittel zur prophylaktischen und therapeutischen Behandlung von EHV-Infektionen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1457202A2 (en) 2003-03-10 2004-09-15 Yung Shin Pharm. Ind. Co. Ltd. Topical formulation comprising a NSAID, preferably diclofenac, for alleviating pain/inflammation caused by herpes virus infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
IT1216686B (it) * 1988-04-01 1990-03-08 Chiesi Farma Spa Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
IT1230922B (it) * 1989-06-23 1991-11-08 Giuseppe De Benedittis Composizione per il trattamento della nevralgia erpetica acuta e della nevralgia post erpetica
ATE95421T1 (de) * 1990-04-26 1993-10-15 Sagitta Arzneimittel Gmbh Piroxicam enthaltende pharmazeutische zusammensetzung zur topischen anwendung.
JP3031990B2 (ja) * 1990-10-19 2000-04-10 同仁医薬化工株式会社 消炎鎮痛クリーム剤組成物
RU2182016C2 (ru) * 1997-03-20 2002-05-10 Панацея Биотек Лтд. Спазмолитическая композиция, способ получения спазмолитической композиции
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
DE102010014290A1 (de) * 2010-04-08 2011-10-13 Hans Otto Meyer zu Spelbrink Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1457202A2 (en) 2003-03-10 2004-09-15 Yung Shin Pharm. Ind. Co. Ltd. Topical formulation comprising a NSAID, preferably diclofenac, for alleviating pain/inflammation caused by herpes virus infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAPADIA,Govind.(et al.):Inhibition of Epstein-Barr virus early antigen activation promoted by 12-O-tetradecanoylphorbol-13- acetate by the non-steroidal anti-inflammatory drugs.In:Cancer Letters 161,2000,S.221-229 NPL *
OGINO,A.(et al.):Therapeutic Effects of Feldene Piroxicam on Herpes Zoster.In:Acta Dermatologica(Kyoto)79(4),1984,S.315-320. ISSN 0065-1176.(Abstract)CAPLUS(Online).2000,Accession No.2000: 829877,In:STN International NPL *

Also Published As

Publication number Publication date
CA2795334C (en) 2015-06-09
DK2374461T3 (en) 2017-02-06
US20140148447A1 (en) 2014-05-29
CA2795334A1 (en) 2011-10-13
WO2011124366A1 (de) 2011-10-13
JP6158077B2 (ja) 2017-07-05
JP2013523789A (ja) 2013-06-17
RU2555765C2 (ru) 2015-07-10
CN103153312B (zh) 2015-07-22
CN103153312A (zh) 2013-06-12
US20130190301A1 (en) 2013-07-25
JP6158077B6 (ja) 2018-08-29
EP2374461B1 (de) 2016-10-26
ES2612584T3 (es) 2017-05-17
RU2012147474A (ru) 2014-05-20
EP2374461A1 (de) 2011-10-12
PL2374461T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
DE69632034T2 (de) Pharmazeutische zubereitung zur topischen applikation enthaltend acyclovir und hydrokortison
DE69527765T2 (de) Verwendung von Hyaluronsäure oder sein Salz zur Behandlung von Hauterkrankungen
DE60109044T2 (de) Arzneimittel zur behandlung der mucositis, stomatitis und des behcetschen syndroms
DE2241740A1 (de) Pharmazeutische packungen
DE2802924A1 (de) Heilmittel zur behandlung von akne
EP0037488B1 (de) Pharmazeutisches Mittel zur Heilung von entzündlichen und/oder degenerativen und/oder atrophischen Schleimhauterkrankungen
DE69825279T2 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
DE102008036725B4 (de) Pharmazeutische Zusammensetzung für die nasale Applikation
DE69730214T2 (de) Zusammensetzung und verfahren zur behandlung von herpes simplex
EP2803354B1 (de) Kombination aus Polyacrylsäure und 2-Amino-2-methylpropanol zur Verwendung in der Behandlung von Herpesinfektionen
EP2374461B1 (de) Piroxicam zur prohylaktischen und therapeutischen Behandlung von Herpes-Infektionen
DE2350721C2 (de) Ophthalmologisches Mittel zur oralen Verabreichung
DE69930725T2 (de) Verfahren und kits zur behandlung von vulvovaginalen candidosen mit mikonazolnitrat
DE69026825T2 (de) Zubereitung für die topische behandlung von infektionen durch viren, bakterien und schimmel
WO2001007035A1 (de) Verwendung von tosylchloramid(en) zur behandlung von erkrankungen der haut, der schleimhaut, von organen und geweben
DE1617306A1 (de) Zahnputzmittel zur Reinigung von Zaehnen und der Verhinderung von Zahnerkrankungen wie Karies oder Zahnfleischentzuendungen
DE202009013734U1 (de) Mineralpulvermischung
DE202007004981U1 (de) Zusammensetzung, insbesondere für die topische Behandlung von Hauterkrankungen
DE19811212C1 (de) Verwendung von aluminiumhaltigen Verbindungen zur Therapie und/oder Prophylaxe von Viruserkrankungen der Haut oder Schleimhaut, die durch Papovaviren verursacht werden
DE69735091T2 (de) Synergistische Gold enthaltende Zusammensetzungen
DE3780702T2 (de) Verwendung von etodolac zur senkung des blutgehalts an harnsaeure.
DE60012183T2 (de) Verwendung einer makrolid-verbindung zur herstellung eines medikaments zur behandlung von gehirnschäden aufgrund von ischämie oder blutungen
DE69906091T2 (de) Verwendung von lithium-gluconat zur herstellung eines arzneimittels zur behandlung von herpes und seborrhoischer dermatitis
DE202005007363U1 (de) Gegen Herpesbläschen verwendbare Kieselsäurezusammensetzungen
EP2120953A1 (de) Zubereitungen für die topische behandlung von hauterkrankungen

Legal Events

Date Code Title Description
R163 Identified publications notified
R012 Request for examination validly filed

Effective date: 20120203

R082 Change of representative

Representative=s name: SCHNEIDERS & BEHRENDT RECHTS- UND PATENTANWAEL, DE

R081 Change of applicant/patentee

Owner name: HOV GMBH, DE

Free format text: FORMER OWNER: HANS OTTO MEYER ZU SPELBRINK,JAN SLOMIANNY, , DE

Effective date: 20130222

Owner name: SLOMIANNY, JAN, DE

Free format text: FORMER OWNER: HANS-OTTO MEYER ZU SPELBRINK,JAN SLOMIANNY, , DE

Effective date: 20130222

Owner name: HOV GMBH, DE

Free format text: FORMER OWNER: HANS-OTTO MEYER ZU SPELBRINK,JAN SLOMIANNY, , DE

Effective date: 20130222

Owner name: SLOMIANNY, JAN, DE

Free format text: FORMER OWNERS: MEYER ZU SPELBRINK, HANS-OTTO, 30169 HANNOVER, DE; SLOMIANNY, JAN, 51588 NUEMBRECHT, DE

Effective date: 20130222

Owner name: HOV GMBH, DE

Free format text: FORMER OWNERS: MEYER ZU SPELBRINK, HANS-OTTO, 30169 HANNOVER, DE; SLOMIANNY, JAN, 51588 NUEMBRECHT, DE

Effective date: 20130222

Owner name: SLOMIANNY, JAN, DE

Free format text: FORMER OWNER: HANS OTTO MEYER ZU SPELBRINK,JAN SLOMIANNY, , DE

Effective date: 20130222

Owner name: MEYER ZU SPELBRINK GMBH, DE

Free format text: FORMER OWNER: HANS OTTO MEYER ZU SPELBRINK,JAN SLOMIANNY, , DE

Effective date: 20130222

R082 Change of representative

Representative=s name: SCHNEIDERS & BEHRENDT PARTMBB, RECHTS- UND PAT, DE

Effective date: 20130222

Representative=s name: SCHNEIDERS & BEHRENDT RECHTS- UND PATENTANWAEL, DE

Effective date: 20130222

R082 Change of representative

Representative=s name: SCHNEIDERS & BEHRENDT RECHTS- UND PATENTANWAEL, DE

R081 Change of applicant/patentee

Owner name: SLOMIANNY, JAN, DE

Free format text: FORMER OWNER: MEYER ZU SPELBRINK GMBH,JAN SLOMIANNY, , DE

Effective date: 20130510

Owner name: HOV GMBH, DE

Free format text: FORMER OWNER: MEYER ZU SPELBRINK GMBH,JAN SLOMIANNY, , DE

Effective date: 20130510

Owner name: HOV GMBH, DE

Free format text: FORMER OWNERS: MEYER ZU SPELBRINK GMBH, 30169 HANNOVER, DE; SLOMIANNY, JAN, 51588 NUEMBRECHT, DE

Effective date: 20130510

Owner name: SLOMIANNY, JAN, DE

Free format text: FORMER OWNERS: MEYER ZU SPELBRINK GMBH, 30169 HANNOVER, DE; SLOMIANNY, JAN, 51588 NUEMBRECHT, DE

Effective date: 20130510

R082 Change of representative

Representative=s name: SCHNEIDERS & BEHRENDT RECHTS- UND PATENTANWAEL, DE

Effective date: 20130510

Representative=s name: SCHNEIDERS & BEHRENDT PARTMBB, RECHTS- UND PAT, DE

Effective date: 20130510

R016 Response to examination communication
R002 Refusal decision in examination/registration proceedings
R003 Refusal decision now final